IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

407

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Melanoma
Unresectable Melanoma

Interventions

DRUG: IO102-IO103
DRUG: Pembrolizumab

Sponsor

IO Biotech

Collaborators

[object Object]
[object Object]